Repatha (evolocumab) injection Repatha (evolocumab) injection

Results from a 12-week study in patients with clinical ASCVD. At week 12, LDL-C was reduced 63% to 77% (mean 71%) with Repatha® 140 mg Q2W + statin more than with placebo + statin.1,2 At week 12, 87% to 90% of patients receiving Repatha® 140 mg Q2W + statin achieved LDL-C < 70 mg/dL

*Maximum-dose statins used in Study 1 were atorvastatin 80 mg, rosuvastatin 40 mg, and simvastatin 40 mg.

Q2W = every 2 weeks.

See additional study design and results.


Self-administered subcutaneously via Repatha® PushtronexTM system single-use on-body infusor with prefilled cartridge. No dose titration needed.
Store Repatha® in the refrigerator. Repatha® is the only PCSK9 inhibitor that can be kept at room temperature (up to 25°C [77°F]) in the original carton prior to use for up to 30 days.1

repatha device

RepathaReady™: Support Services



with the Repatha® Copay Card

See Repatha® Copay Card program details.     open eligibility requirements close eligibility requirements

Eligibility Requirements for Repatha® Copay Card: Offer is available to patients with commercial insurance and applies to deductible, coinsurance, and copay for Repatha®. This program is not open to patients receiving prescription reimbursement under any federal, state or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law.

copay card

*No titration needed with once monthly or every two weeks dosing schedule.


  1. Repatha® (evolocumab) Prescribing Information, Amgen.
  2. Data on file, Amgen; 2015.
  3. Data on file, Amgen; 2015.
See MoreClose


Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse reactions: The most common adverse reactions (> 5% of Repatha®-treated patients and more common than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Adverse reactions from a pool of the 52-week trial and seven 12-week trials:
Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients.

In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1,988 patients treated with Repatha® had at least one LDL‑C value < 25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and Repatha® dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the long-term effects of very low levels of LDL-C induced by Repatha® are unknown.

Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%).

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.


Repatha® is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C).

The effect of Repatha® on cardiovascular morbidity and mortality has not been determined.